Beyond AR: New Approaches to Treating Metastatic Prostate Cancer

June 20-23, 2013
Hyatt Regency
Lake Tahoe, Nevada

Program Committee
Ken Pienta, M.D. Chair (Johns Hopkins University)
John Isaacs, Ph.D. (Johns Hopkins University)
Phil Kantoff, M.D. (Dana-Farber Cancer Center)
Peter Nelson, M.D. (Fred Hutchinson Cancer Research Center)
Howard Soule, Ph.D. (Prostate Cancer Foundation)
Owen Witte, M.D. (UCLA)
THURSDAY, JUNE 20, 2013

3:00 PM - 7:00 PM  Arrival/Check-In & Registration
                   Registration Desk
                   Regency Foyer

5:00 PM - 6:00 PM  Reception
                   Mike Milken Lakeshore Home

6:00 PM - 7:30 PM  Dinner
                   Mike Milken Lakeshore Home

Session I: Introduction and Charge for Participants
Location: Mike Milken Lakeshore Home

7:30 PM - 8:00 PM  Welcome and Opening Remarks
Ken Pienta, MD
Howard Soule, PhD

History of Prouts Neck
Donald Coffey, PhD

8:00 PM - 9:00 PM  Global & Personal Perspectives
Mike Milken

FRI DAY, JUNE 21, 2013

Session II: Charge to Participants: The Big Questions
Location: Regency Ballroom DEF

7:00 AM - 7:45 AM  Breakfast
Regency Ballroom DEF

8:00 AM - 9:00 AM  The Big Questions
Ken Pienta, MD

Session III: Extrinsic (Microenvironment) Factors Modulating Prostate Cancer Therapy Resistance
Location: Regency Ballroom DEF

Session Chair: Ralph Buttyan, PhD

9:00 AM - 9:10 AM  Stromal Mediators of Resistance
Peter Nelson, MD
Fred Hutchinson Cancer Research Center

9:10 AM - 9:30 AM  Discussion
First Question: Mark Pomerantz
9:30 AM - 9:40 AM DNA Damage-Induced Signaling and the Survival of Minimal Residual Disease
**Michael Hemann, PhD**
Massachusetts Institute of Technology

9:40 AM – 10:00 AM Discussion
First Question: Chad Brenner

10:00 AM - 10:10 AM Role of Epithelial to Mesenchymal Transition in Prostate Cancer Therapy Resistance
**Rob Reiter, MD**
David Geffen School of Medicine at UCLA

10:10 AM - 10:30 AM Discussion
First Question: Jennifer Bishop

10:30 AM – 10:40 AM Break
Regency Foyer

10:40 AM - 10:50 AM A Strategy to Improve Cancer Therapy Models in Mice to Better Predict Outcomes of Patients with Metastatic Disease
**Robert S. Kerbel, PhD**
University of Toronto

10:50 AM - 11:10 AM Discussion
First Question: John Isaacs

11:10 AM - 11:20 AM Stromal and Epithelial Mediators of Resistance to Immunotherapy for Prostate Cancer
**Charles Drake, MD, PhD**
Johns Hopkins University

11:20 AM - 11:40 AM Discussion
First Question: Guneet Walia

11:40 AM -11:50 AM A Different Look at the Hallmarks of Cancer
**Yuzhuo Wang, PhD**
The Vancouver Prostate Centre

11:50 AM - 12:10 PM Discussion
First Question: Yu Chen

12:10 PM -12:20 PM The Association Between the Stem Cell State and Prostate Cancer Resistance - Evaluating the Role of the Microenvironment and Treatment Effects in Promoting Lethal Disease
**Isla Garraway, MD, PhD**
David Geffen School of Medicine at UCLA

12:20 PM - 12:40 PM Discussion
First Question: Chris Maher
12:40 PM - 1:40 PM  Lunch  
Water Garden I

1:40 PM - 2:00 PM  Move to Session

Session IV: Defeating Therapeutic Resistance  
Location: Regency Ballroom DEF

Session Chair:  Mark Rubin, MD

2:00 PM - 2:10PM  
Introduction to Session  
Mark Rubin, MD  
Weill Cornell Medical College

2:10 PM - 2:20 PM  
Co-Targeting Adaptive Stress Response Pathways to Manipulate Sensitivity of Cancer Cells to Therapy  
Martin Gleave, MD  
University of British Columbia

2:20 PM - 2:40 PM  Discussion  
First Question: Joshua Lang

2:40 PM - 2:50 PM  
Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities  
James Allison, PhD  
The University of Texas MD Anderson Cancer Center

2:50 PM - 3:10 PM  Discussion  
First Question: Akash Patnaik

3:10 PM - 3:20 PM  
Investigating Anti-CTLA-4 as Treatment for Prostate Cancer  
Padmanee Sharma, MD, PhD  
The University of Texas MD Anderson Cancer Center

3:20 PM - 3:40 PM  Discussion  
First Question: Felix Feng

3:40 PM - 3:50 PM  
Defining Kinase Targets in Advanced Prostate Cancer  
Justin Drake, PhD  
University of California, Los Angeles

3:50 PM - 4:10 PM  Discussion  
First Question: Hannelore Heemers

4:10 PM - 4:20 PM  
Implementing a Precision Cancer Medicine Program  
Sameek Roychowdhury, MD, PhD  
The Ohio State University

4:20 PM - 4:40 PM  Discussion  
First Question: Don Coffey
Friday, June 21, 2013

4:40 PM - 4:50 PM  Microenvironment Targeting of Angiogenesis  
                  Amado Zurita, MD  
                  The University of Texas MD Anderson Cancer Center

4:50 PM - 5:10 PM  Discussion  
                  First Question: Ralph Buttyan

6:00 PM - 8:00 PM  Dinner  
                  Lakeside Ballroom A

Session V: Plenary Session  
Location: Regency Ballroom DEF

8:30 PM - 10:00 PM  Roundtable Discussion:  
                    What Should We Be Thinking About?  
                    Moderator: Howard Soule, PhD  
                    Participants:  
                    Robert S. Kerbel, PhD  
                    Martin Gleave, MD  
                    James Allison, PhD  
                    Owen Witte, MD

SATURDAY, JUNE 22, 2013

6:30 AM - 7:15 AM  Meet in the Lobby  
                   “Sunrise Ceremony”  
                   Donald Coffey, PhD

7:15 AM - 8:15 AM  Breakfast  
                   Beach Barbeque Area

8:15 AM - 8:30 AM  Move to Session

Session VI: The AR Binding Domain and Beyond  
Location: Regency Ballroom DEF  
Session Chair: Peter Nelson, MD

8:30 AM - 8:40 AM  Introduction to Session  
                   Peter Nelson, MD  
                   Fred Hutchinson Cancer Research Center

8:40 AM - 8:50 AM  Targeting Oncogenic Pathways in Prostate Cancer: the SAGA Continues  
                   Karen Knudsen, PhD  
                   Thomas Jefferson University

8:50 AM - 9:10 AM  Discussion  
                   First Question: Scott Tomlins
9:10 AM - 9:20 AM  
**SOX9 Regulated Wnt Signaling in TMPRSS2: ERG Fusion Positive and Negative PCa**  
*Steven Balk, MD, PhD*  
Beth Israel Deaconess Medical Center

9:20 AM - 9:40 AM  
Discussion  
First Question: Nicholas Nickols

9:40 AM - 9:50 AM  
**Have We Addressed the Use of the Androgen Receptor by Prostate Cancer?**  
*Stephen Plymate, MD*  
University of Washington

9:50 AM - 10:10 AM  
Discussion  
First Question: Stephen Finn

10:10 AM - 10:20 AM  
**Targeting Transcription Downstream of the Nuclear Receptors**  
*Nicholas Mitsiades, MD, PhD*  
Baylor College of Medicine

10:20 AM - 10:40 AM  
Discussion  
First Question: Matthew Galsky

10:40 AM - 10:50 AM  
**Are We Done With Hormone Therapy?**  
*Gerhardt Attard, MD, PhD*  
The Institute of Cancer Research & Royal Marsden Hospital

10:50 AM - 11:10 AM  
Discussion  
First Question: Tarek Bismar

11:10 AM - 11:20 AM  
Break  
*Regency Foyer West*

11:20 AM - 11:30 AM  
**Understanding the Neuroendocrine Phenotype as Mechanism of Treatment Resistance**  
*Himisha Beltran, MD*  
Weill Cornell Medical College

11:30 AM - 11:50 AM  
Discussion  
First Question: Rohit Mehra

11:50 AM - 12:00 PM  
**Targeting Aberrant Translational Regulons in Prostate Cancer**  
*Andrew Hsieh, MD*  
University of California, San Francisco

12:00 PM - 12:20 PM  
Discussion  
First Question: Michael Haffner

12:20 PM - 1:20 PM  
Lunch  
*Martis Peak ABC*

1:20 PM - 6:00 PM  
Afternoon Free

6:00 PM - 7:30 PM  
Dinner  
*Castle Peak AB*
Session VII: Plenary Session  
Location: Regency Ballroom DEF  
8:00 PM - 10:00 PM Brainstorming  
William Nelson, MD, PhD  
Johns Hopkins University

SUNDAY, JUNE 23, 2013

6:30 AM - 7:30 AM Breakfast  
Regency Ballroom DEF  
*Hotel checkout before 12 noon

Session VIII: What are we forgetting?  
Location: Regency Ballroom DEF

Session Chair: Phil Kantoff

7:30 AM - 7:40 AM Genesis of Reactive Stroma and Prostate Cancer Progression  
David Rowley, PhD  
Baylor College of Medicine

7:40 AM - 8:00 AM Discussion  
First Question: Barbara Lelj-Garolla Di Bard

8:00 AM - 8:10 AM Of Men, Mice, and Prostate Cancer  
Colin Collins, PhD  
University of British Columbia

8:10 AM - 8:30 AM Discussion  
First Question: Mark Rubin

8:30 AM - 8:40 AM Targeting Apoptosis and Epigenetics Regulators for New Therapeutics for Prostate Cancer  
Shaomeng Wang, PhD  
University of Michigan

8:40 AM - 9:00 AM Discussion  
First Question: Jonathan Simons

9:00 AM - 9:10 AM Transitioning from Drug to Therapy Development  
Christopher Logothetis, MD  
The University of Texas MD Anderson Cancer Center

9:10 AM - 9:30 AM Discussion  
First Question: Alexander Wyatt
9:30 AM - 9:40 AM  Targeting Epigenetic Programs for Prostate Cancer Therapy  
Srinivasan Yegnasubramanian, MD  
Johns Hopkins University

9:40 AM - 10:00 AM  Discussion  
First Question: Amina Zoubeidi

10:00 AM - 10:10 AM  Bipolar Therapy for CRPC  
John Isaacs, PhD  
Johns Hopkins University

10:10 AM - 10:30 AM  Discussion  
First Question: Lorelei Mucci

10:30 AM - 10:40 AM  Applications of Functional PET Imaging in Prostate Cancer: Focus on PSMA  
Steve Cho, MD  
Johns Hopkins University

10:40 AM - 11:00 AM  Discussion  
First Question: Stuart Holden

11:00 AM - 11:15 AM  Meeting Debrief  
Ken Pienta, MD  
Johns Hopkins University

11:15 AM  Lunch & Departures